The promise of the first new Alzheimer's drug in nearly 2 decades

The promise of the first new Alzheimer's drug in nearly 2 decades
Hollis Johnson/Business Insider

Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.

Hello,

While we wait to hear more about the results of the presidential election, here's the latest in healthcare news.
Advertisement
Today: Good news for Biogen's experimental Alzheimer's drug, why massive health insurers like UnitedHealth Group are surging, and the US surpasses 103,000 daily COVID-19 cases, the highest single-day count since the pandemic began.

79064327

Biogen just gained $16 billion in market value, as investors increasingly expect approval of the first Alzheimer's drug in over 15 years. Here's what comes next.

  • What could be the first disease-modifying Alzheimer's drug got a step closer to US approval on Wednesday.
  • The US Food and Drug Administration released crucial documents Wednesday summarizing the evidence for and against Biogen's experimental treatment called aducanumab.
  • The FDA documents stated Biogen has "provided substantial evidence of effectiveness to support approval."
  • The agency is aiming to make a decision on aducanumab by March 7, 2021 at the latest.

Read the full story from Andrew Dunn here>>

79064328

Massive healthcare companies like UnitedHealth Group and Anthem are soaring in the wake of an undecided election — and it's because an overhaul of health insurance is looking less likely

Read the full story from Shelby Livingston here>>
Advertisement

79064331

The US surpassed 103,000 new daily COVID-19 cases, the highest single-day count in the entire pandemic. And the deadliest wave is yet to come.

Read the full story from Sarah Al-Arshani here>> More stories we're reading:
Advertisement

Subscribe to our newsletter here!

- Lydia

{{}}